Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress

Century Therapeutics

PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has announced its participation in the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, set to take place from June 11-14 at Fira de Barcelona in Spain. The company will present new data highlighting progress in its preclinical cell therapy pipeline and investigative programs targeting autoimmune diseases and cancer.

The presentations will showcase Century’s innovative approach leveraging induced pluripotent stem cells (iPSCs) as the foundation for off-the-shelf therapies aimed at addressing complex conditions. Key details are as follows:

  • Abstract Number 1380
    Title: CNTY-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Exhibits Robust B Cell Depletion and Has Broad Potential for Development in B Cell-Driven Autoimmune Diseases
    Presentation Type: Poster Tour
    Session Date/Time: Thursday, June 12, 2025, 9:30 a.m.–9:36 a.m. CEST
    Presenter: Hongxia Zhang, Ph.D., Director of Translational Development
  • Abstract Number 2099
    Title: Generation of iPSC-Derived CAR-NK, γδ CAR-T, and αβ CAR-T Cells with Potent Activity for Treatment of B cell-mediated Autoimmune Diseases
    Presentation Type: Poster Tour
    Session Date/Time: Thursday, June 12, 2025, 9:42 a.m.–9:48 a.m. CEST
    Presenter: Jonathan Kurtz, Ph.D., Director of Molecular Immunology

The data covers key developments in CNTY-101, an allogeneic CD19-targeting CAR-NK product, which demonstrates strong B cell depletion capabilities and potential applications in B cell-driven autoimmune diseases. Additionally, insights into Century’s pipeline of iPSC-derived CAR-NK and CAR-T cells for B cell-mediated conditions will be provided, reflecting the company’s commitment to addressing unmet medical needs in immune-related diseases.

Century Therapeutics advances its platform to create potent, scalable, and targeted cell therapies. Presentations at EULAR 2025 highlight the company’s efforts in iPSC-based therapies and dedication to improving outcomes for patients with autoimmune diseases and cancers.

READ:  Comcast Announces Quarterly Dividend of $0.33 per Share

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.